Parexel launches advisory service dedicated to Chinese market

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Tuangtong)
(Image: Getty/Tuangtong)

Related tags: China, Parexel, Clinical trials

Parexel is launching a new advisory service to help clients navigate the market opportunities in China.

The biopharmaceutical services provider has launched a new China Advisory Service. The offering includes overall strategy, agency engagement and agreements, early development, clinical operations, and regulatory, market access, and commercial strategies support.

Several regulatory changes in China over the past few years​ are expected to accelerate drug development timelines.

Earlier this year, the Chinese Premier Li Keqiang announced​ several developments during an executive meeting of the State Council of the People's Republic of China last month. Of the highlighted developments, plans include those “to enhance quality supervision,” establish “intensified on-site inspection of foreign drugs’ production,” and double down on counterfeit drugs, according to the release from the State Council.

Read more: Chinese gov't outlines changes to import tariff, clinical trial applications, IP protection

China also now accepts clinical trial data from other countries following a new guideline released last yea​r that aims to reform the management of clinical trials.

Over the next 10 years, the Chinese market is expected to see “high growth,”​ as health care currently accounts for just 7% of the overall government expense – leaving room to expand, Mingping Zhang, vice president, technical, Parexel Consulting, told us in June.

The Chinese pharmaceutical market recently outpaced Japan to become the second largest market globally.

Parexel has been operating in China for more than 19 years and employs more than 1,400 employees in seven offices across the country.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us


View more